(19)
(11) EP 2 614 140 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.10.2018 Bulletin 2018/42

(45) Mention of the grant of the patent:
08.08.2018 Bulletin 2018/32

(21) Application number: 11823761.9

(22) Date of filing: 06.09.2011
(51) International Patent Classification (IPC): 
C12N 5/071(2010.01)
A61K 39/145(2006.01)
 C12N 5/02(2006.01)
C12N 7/00(2006.01)
(86) International application number:
PCT/KR2011/006589
(87) International publication number:
WO 2012/033328 (15.03.2012 Gazette 2012/11)

(54)

MDCK-DERIVED CELL LINES ADAPTED TO SERUM-FREE CULTURE AND SUSPENSION CULTURE AND METHOD FOR PREPARING VACCINE VIRUS USING THE CELLS

AN EINE SERUMSFREIE KULTUR ANGEPASSTE MDCK-ZELLLINIEN, SUSPENSIONSKULTUR DAMIT UND VERFAHREN ZUR HERSTELLUNG EINES IMPFSTOFFS MIT DIESEN ZELLEN

LIGNÉES CELLULAIRES DÉRIVÉES DE MDCK ADAPTÉES À LA CULTURE SANS SÉRUM ET À LA CULTURE EN SUSPENSION ET PROCÉDÉ DE PRÉPARATION D'UN VIRUS DE LA VACCINE UTILISANT LESDITES CELLULES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.08.2011 KR 20110085902
06.09.2010 WO PCT/KR2010/006041

(43) Date of publication of application:
17.07.2013 Bulletin 2013/29

(73) Proprietor: SK Bioscience Co., Ltd.
Seongnam-si, Gyeonggi-do 13494 (KR)

(72) Inventors:
  • PARK, Yong Wook
    Suwon-si Gyeonggi-do 442-192 (KR)
  • LEE, Kun Se
    Seoul 138-797 (KR)
  • LEE, Bong-yong
    Seoul 137-060 (KR)
  • PARK, Mahnhoon
    Yongin-si Gyeonggi-do 446-902 (KR)
  • KIM, Hun
    Suwon-si Gyeonggi-do 442-754 (KR)
  • KIM, Yun-hee
    Seongnam-si Gyeonggi-do 463-856 (KR)
  • LEE, Su-jeen
    Ansan-si Gyeonggi-do 426-706 (KR)

(74) Representative: Peters, Hajo et al
ZACCO GmbH Bayerstrasse 83
80335 München
80335 München (DE)


(56) References cited: : 
WO-A1-2012/033236
DE-A1- 10 144 906
 WO-A2-2008/032219
US-B2- 6 825 036
   
  • SAFC BIOSCIENCES: 'Suspension MDCK Cell Culture in EX-CELL(TM) MDCK Serum-F ree Medium' TECHNICAL BULLETIN March 2006,
  • CHU, C. ET AL.: 'Conversion of MDCK cell line to suspension culture by tra nsfecting with human siat7e gene and its application for influenza virus pro duction' PNAS vol. 106, no. 35, 01 September 2009, pages 14802 - 14807
  • GEORGE, M. ET AL.: 'Production of Cell Culture (MDCK) Derived Live Attenua ted Influenza Vaccine (LAIV) in a Fully Disposable Platform Process' BIOTE CHNOLOGY AND BIOENGINEERING vol. 106, no. 6, 15 August 2010, pages 906 - 917
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).